Minimizing adverse events associated with poly-L-lactic acid injection

Dermatologic Surgery

Volumn 34, Issue SUPPL 1, 2008, Pages

  Narins, Rhoda S ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dermatology Surgery and Laser Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIC ACID;

ADVERSE OUTCOME; FACIAL LIPOATROPHY; HUMAN; INJECTION SITE REACTION; LIPOATROPHY; MASSAGE; PAPULE; PRIORITY JOURNAL; REVIEW; SAFETY; SKIN NODULE; THERAPY EFFECT;

CELLULOSE; COSMETIC TECHNIQUES; DRUG COMPOUNDING; FACE; FEMALE; GRANULOMA, FOREIGN-BODY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERSENSITIVITY, DELAYED; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MANNITOL; MASSAGE; POLYMERS; SKIN; SKIN AGING; SKIN DISEASES;

EID: 44849099601     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2008.34250.x     Document Type: Review

References (18)

1. Barton SE, Engelhard P, Conant M. Poly-l-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. Int J STD AIDS 2006 17 : 429 35.
2. Borelli C, Kunte C, Weisenseel P, et al. Deep subcutaneous application of poly-l-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol 2005 18 : 273 8.
3. Mest DR, Humble G. Safety and efficacy of poly-l-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 2006 32 : 1336 45.
4. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. Aids 2003 17 : 2471 7.
5. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993 27 : 1135 48.
6. Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). J Drugs Dermatol 2004 3 : 542 7.
7. Tunc DC, Jadhav B. Development of absorbable, ultra high strength poly(lactides). In : Gebelein CG, Dunn RL, eds. Progress in biomedical polymers. New York : Plenum Press, 1990 : 239 48.
8. Moyle GJ, Brown S, Lysakova L, et al. Long-term safety and efficacy of poly-l-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006 7 : 181 5.
9. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-l-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005 52 : 233 9.
10. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004 5 : 82 7.
11. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg 2005 31 (11 Pt 2) : 1616 25.
12. Engelhard P, Humble G, Mest D. Safety of sculptra: a review of clinical trial data. J Cosmet Laser Ther 2005 7 (3-4) : 201 5.
13. Vleggaar D. Soft-tissue augmentation and the role of poly-l-lactic acid. Plast Reconstr Surg 2006 118 (3 Suppl) : 46S 54S.
14. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers. J Derm Surg 2005 31 : 1616 25.
15. Lam SM, Azizzadeh B, Graivier M. Injectable poly-l-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg 2006 118 (3 Suppl) : 55S 63S.
16. ® Product Information. sanofi-aventis; 2006. Available from :. Accessed August 6, 2007.
17. Vleggaar D. Poly-l-lactic acid: consultation on the injection techniques. J Eur Acad Dermatol Venereol 2006 20 (Suppl 1) : 17 21.
18. Butterwick K. Understanding injectable Poly-l-lactic acid. Cosmet Dermatol 2007 20 : 388 92.